Home » Stocks » PHAT

Phathom Pharmaceuticals, Inc. (PHAT)

Stock Price: $39.66 USD 0.64 (1.64%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 1.12B
Revenue (ttm) n/a
Net Income (ttm) -173.35M
Shares Out 33.37M
EPS (ttm) -23.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $39.66
Previous Close $39.02
Change ($) 0.64
Change (%) 1.64%
Day's Open 38.44
Day's Range 38.44 - 40.00
Day's Volume 130,040
52-Week Range 24.65 - 54.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 days ago

FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing no...

Business Wire - 2 weeks ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice Presid...

Other stocks mentioned: PASG
GlobeNewsWire - 1 month ago

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing no...

GlobeNewsWire - 1 month ago

FLORHAM PARK, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing no...

GlobeNewsWire - 1 month ago

Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET) Management and Key Opinion Leaders to d...

Zacks Investment Research - 1 month ago

Phathom Pharmaceuticals (PHAT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

Topline results expected in second half of 2021 Topline results expected in second half of 2021

GlobeNewsWire - 1 month ago

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing no...

GlobeNewsWire - 2 months ago

FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing no...

GlobeNewsWire - 2 months ago

FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing no...

GlobeNewsWire - 4 months ago

FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing...

GlobeNewsWire - 5 months ago

FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing ...

GlobeNewsWire - 6 months ago

FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing ...

GlobeNewsWire - 7 months ago

First New Patients Randomized in PHALCON-EE and PHALCON-HP Trials Since Temporary Pause Announced in March First New Patients Randomized in PHALCON-EE and PHALCON-HP Trials Since Temporary Pau...

GlobeNewsWire - 8 months ago

FLORHAM PARK, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing n...

Seeking Alpha - 11 months ago

Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020

About PHAT

Phathom Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 25, 2019
CEO
Terrie J. Curran
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
PHAT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is 51.33, which is an increase of 29.43% from the latest price.

Price Target
$51.33
(29.43% upside)
Analyst Consensus: Buy